tyrosine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
2786 60-18-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • tyrosine
  • L-Tyrosine
  • (S)-Tyrosine
A non-essential amino acid. In animals it is synthesized from PHENYLALANINE. It is also the precursor of EPINEPHRINE; THYROID HORMONES; and melanin.
  • Molecular weight: 181.19
  • Formula: C9H11NO3
  • CLOGP: -2.22
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 3
  • TPSA: 83.55
  • ALOGS: -1.37
  • ROTB: 3

  • Status: OFM

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
None FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Foetal growth restriction 51.55 24.32 15 1270 6552 46678225
Infantile apnoea 39.45 24.32 8 1277 768 46684009
Sinus arrest 33.06 24.32 8 1277 1723 46683054
Selective eating disorder 33.00 24.32 8 1277 1737 46683040
Device related sepsis 27.97 24.32 8 1277 3279 46681498
Sinus node dysfunction 25.87 24.32 8 1277 4281 46680496

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Eye infection 33.25 30.89 9 871 2833 29948765
Somnambulism 32.15 30.89 9 871 3205 29948393

Pharmacologic Action:

SourceCodeDescription
CHEBI has role CHEBI:27027 trace elements
CHEBI has role CHEBI:50733 nutritional supplement
CHEBI has role CHEBI:64416 tyra(a) inhibitor
CHEBI has role CHEBI:78675 essential metabolite
CHEBI has role CHEBI:83056 daphnia magna metabolites

Drug Use (View source of the data)

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.27 acidic
pKa2 10.4 acidic
pKa3 9.25 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
4018678 VUID
N0000146989 NUI
D00022 KEGG_DRUG
4018678 VANDF
C0041485 UMLSCUI
CHEBI:17895 CHEBI
TYR PDB_CHEM_ID
6057 PUBCHEM_CID
CHEMBL925 ChEMBL_ID
DB00135 DRUGBANK_ID
D014443 MESH_DESCRIPTOR_UI
4791 IUPHAR_LIGAND_ID
6174 INN_ID
42HK56048U UNII
10962 RXNORM
15487 MMSL
187423 MMSL
NOCODE MMSL
d07831 MMSL
003449 NDDF
27378009 SNOMEDCT_US
418246001 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
TrophAmine HUMAN PRESCRIPTION DRUG LABEL 20 0264-1933 SOLUTION 0.04 g INTRAVENOUS NDA 23 sections
Plenamine HUMAN PRESCRIPTION DRUG LABEL 17 0264-3200 SOLUTION 39 mg INTRAVENOUS ANDA 20 sections
Plenamine HUMAN PRESCRIPTION DRUG LABEL 17 0264-3205 SOLUTION 39 mg INTRAVENOUS ANDA 20 sections
Plenamine HUMAN PRESCRIPTION DRUG LABEL 17 0264-4500 SOLUTION 39 mg INTRAVENOUS ANDA 20 sections
TrophAmine HUMAN PRESCRIPTION DRUG LABEL 20 0264-9341 SOLUTION 0.04 g INTRAVENOUS NDA 23 sections
TrophAmine HUMAN PRESCRIPTION DRUG LABEL 20 0264-9361 SOLUTION 0.04 g INTRAVENOUS NDA 23 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0180 INJECTION 32 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0184 INJECTION, EMULSION 32 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0188 INJECTION 32 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0194 INJECTION 32 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0198 INJECTION 24 mg INTRAVENOUS NDA 21 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0202 INJECTION 32 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0206 INJECTION 32 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0210 INJECTION 32 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0214 INJECTION 32 mg INTRAVENOUS NDA 20 sections
ProSol HUMAN PRESCRIPTION DRUG LABEL 17 0338-0499 INJECTION, SOLUTION 50 mg INTRAVENOUS NDA 21 sections
Clinisol HUMAN PRESCRIPTION DRUG LABEL 17 0338-0502 INJECTION, SOLUTION 39 mg INTRAVENOUS ANDA 18 sections
Travasol HUMAN PRESCRIPTION DRUG LABEL 15 0338-0644 INJECTION 40 mg INTRAVENOUS NDA 20 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-1089 INJECTION 17 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-1091 INJECTION 17 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-1099 INJECTION 20 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-1101 INJECTION 20 mg INTRAVENOUS NDA 21 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-1113 INJECTION 17 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-1115 INJECTION 17 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-1123 INJECTION 20 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-1125 INJECTION 20 mg INTRAVENOUS NDA 20 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-1133 INJECTION 17 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-1134 INJECTION 17 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-1137 INJECTION 20 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-1138 INJECTION 20 mg INTRAVENOUS NDA 21 sections